Biotechnology

Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results

April 22, 2024 9:00 AM

VICTORIA, BC / ACCESSWIRE / April 22, 2024 / ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already successful LENSai TM Platform. LENSai, which is run by the company's subsidiary, BioStrand, provides a unique and comprehensive view of life sciences data by linking sequence, structure, function and literature information from the entire...

Read more

Intellistem, Inc. to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

April 22, 2024 8:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / April 22, 2024 / Intellistem, Inc, (private), is the developer of an innovative Cell Therapy that has shown reduced or eliminated tumors in 30 patients, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 10:30AM (Local Time -PST). Bill St John, CEO of Intellistem Inc. will be hosting the presentation and answering questions at the conclusion. To...

Read more

Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split

April 19, 2024 12:10 PM

BOSTON, MA / ACCESSWIRE / April 19, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on April 23, 2024, under the Company's...

Read more

Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published

April 19, 2024 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / April 19, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the Company's webcast presentation and discussion during the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 17, 2024 is...

Read more

Form Bio Establishes Scientific Advisory Board, Comprised of Renowned Experts in Cell and Gene Therapy, for Advancing AI-Driven Therapies

April 18, 2024 8:00 AM

Bringing Together the Top Minds Across Vector Engineering, Viral Vector Delivery Systems and Next-Generation Gene Transfer Technologies Further Cements Form Bio's Position as a Leader in AI-Driven Cell and Gene Therapy DALLAS, TX / ACCESSWIRE / April 18, 2024 / Form Bio, the breakthrough computational life sciences solutions provider, today announced the creation of a new Scientific Advisory Board (SAB). This esteemed board will provide...

Read more

Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)

April 16, 2024 9:15 AM

(Please see important safety information below) NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Petros Pharmaceuticals, Inc. ("Petros," or the "Company") (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces it has received positive feedback from the U.S. Food and Drug Administration (the "FDA," or the "Agency") following the FDA's informal review of Petros'...

Read more

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024

April 16, 2024 9:00 AM

IRVINE, CA / ACCESSWIRE / April 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that additional topline efficacy data from the VenoValve U.S. pivotal trial will be presented at the 2024 Charing Cross International Symposium being held April 23rd - 25th in London, England. The presentation, entitled "Efficacy Results of...

Read more

Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run

April 16, 2024 8:00 AM

NORTH PALM BEACH, FL / ACCESSWIRE / April 16, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, announces that it is embarking on a fresh manufacturing run to ensure Pritumumab ("PTB") supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial. "Taking the time...

Read more

AmplifyBio and RNAV8 Bio Announce Strategic Partnership to Support mRNA Therapeutic Developers from Sequence Design to GMP Manufacture

April 16, 2024 7:00 AM

NEW ALBANY, OH / ACCESSWIRE / April 16, 2024 / AmplifyBio, a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) focused on differentiating services that cover target optimization, preclinical safety studies, and manufacturing scale-up, and RNAV8 Bio, an emerging startup focused on mRNA engineering platforms, are partnering to provide a one-stop shop for the development of mRNA therapeutics. The...

Read more

Biolog Expands the Odin Family, and Access to Cellular Characterization, With the Launch of Odin VIII

April 16, 2024 7:00 AM

HAYWARD, CA / ACCESSWIRE / April 16, 2024 / Biolog, Inc., a leading provider of cell-based microbial identification and phenotypic and metabolic profiling products and services, today announced the launch of OdinTM VIII system, the newest member of its Odin family of instruments. Designed to meet the needs of laboratories with mid-throughput requirements, Odin VIII is a smaller yet equally powerful version of the Odin platform introduced last...

Read more

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

April 15, 2024 8:31 AM

Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug conjugates and platform innovation BRIDGEWATER, NJ / ACCESSWIRE / April 15, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology announced today the formation of a new Scientific...

Read more

Ondine Biomedical Inc. Announces 32% Fewer SSIs After Steriwave Replaced Mupirocin

April 15, 2024 2:00 AM

New data shows reduced cardiac infections and significant cost savings after the light-activated antimicrobial, Steriwave, replaced the antibiotic standard of care at the Mazankowski Alberta Heart Institute VANCOUVER, BC / ACCESSWIRE / April 15, 2024 / Ondine Biomedical Inc. (LON:OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that an independent study undertaken at the world renowned...

Read more

Update on Formulation of New Business Strategy

April 12, 2024 9:27 AM

INFORMATION ON ENZOLYTICS, INC. BOARD OF DIRECTORS AND CHIEF EXECUTIVE OFFICER UPDATE ON FORMULATION OF NEW BUSINESS STRATEGY ALLEN, TX / ACCESSWIRE / April 12, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com) (the "Company") today released resume information on its new board of directors and chief financial officer. The new board of directors consists of Harry Zhabilov, Chairman; Dr. Lachezar Ivanov, and Dr. Gaurav Chandra....

Read more

ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments

April 12, 2024 9:00 AM

VICTORIA, BC / ACCESSWIRE/ April 12, 2024 / InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability and speed challenges partnered with ImmunoPrecise Antibodies (NASDAQ:IPA) ("IPA"), an artificial intelligence-driven biotherapeutic research and technology company in what they stated is a landmark collaboration. Featured photo by CDC on Unsplash. Between June 2022...

Read more

Vicore to Present at Upcoming Investor Conferences

April 12, 2024 5:20 AM

STOCKHOLM, SE / ACCESSWIRE / April 12, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, April 12, 2024 - Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following investor conferences: Kempen Life Sciences Conference Location: Amsterdam, Holland Date: April 16 Company Participants: Hans Jeppsson, CFO, and Bertil...

Read more

DiviTum(R) TKa in Observational Trial

April 12, 2024 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / April 12, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, today announces that a observational trial with DiviTum TKa has started at Mayo Clinic in Florida. If successful, it will further validate the utility of DiviTum TKa as an effective tool for disease monitoring. "The study evaluates DiviTum TKa's capacity as a predictive blood-based biomarker that can...

Read more

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

April 11, 2024 9:00 AM

TORONTO, ON / ACCESSWIRE / April 11, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for April 16-17, 2024 in Toronto, Ontario. Edesa's Chief Executive Officer Par Nijhawan, MD, is scheduled to present on...

Read more

MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

April 11, 2024 9:00 AM

Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, 2024, respectively Acceptance period has commenced and will end on May 13, 2024, at 24:00 hours CEST PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 11, 2024 / The Management Board and Supervisory...

Read more

Nomination Committee for Biovica International AB for the 2024 Annual General Meeting

April 11, 2024 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / April 11, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The Nomination Committee prior to the 2024 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2023, and the Chairman of the Board. The Nomination Committee then appoints a...

Read more

Ondine Biomedical Inc. Announces Steriwave Authorized for use by HCA UK

April 10, 2024 2:00 AM

Steriwave authorized for use by HCA UK Light-activated antimicrobial that does not generate antimicrobial resistance (AMR) approved for use in healthcare facilities operated by leading private healthcare provider HCA Healthcare UK VANCOUVER, BC / ACCESSWIRE / April 10, 2024 / Leading private healthcare provider, HCA Healthcare UK, has approved the Steriwave® light-activated antimicrobial developed by Ondine Biomedical Inc. (LON:OBI) for use in...

Read more